All In Biotech

NDA 210491 · Vertex Pharms INC

Symdeko (Copackaged)

Ivacaftor, Ivacaftor, Tezacaftor · Oral

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Feb 12, 2018

Approved uses

3

Original approval plus efficacy supplements

Registered trials

136

60 Phase 3, 11 recruiting

FAERS reports

5,288

3,301 serious, 74 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 21, 2026.

SYMDEKO is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. SYMDEKO is a combination of tezacaftor and ivacaftor, indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. ( 12.1 , 14 ) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. ( 1 )

Mechanism: Tezacaftor facilitates the cellular processing and trafficking of select mutant forms of CFTR (including F508del-CFTR) to increase the amount of mature CFTR protein delivered to the cell surface. Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface. For ivacaftor to function CFTR protein must be present at the cell surface. Ivacaftor can potentiate the CFTR protein delivered to the cell surface by tezacaftor, leading to a further enhancement of chloride transport than...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 21, 2020 Supplement 7 · Efficacy · priority review OrphanLetterLabel
  • Jun 21, 2019 Supplement 3 · Efficacy · priority review OrphanLetterLabel
  • Feb 12, 2018 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
  • SYMDEKO (COPACKAGED) · IVACAFTOR 150MG; IVACAFTOR, TEZACAFTOR 150MG, 100MG · TABLET, ORAL · Prescription
  • SYMDEKO (COPACKAGED) · IVACAFTOR 75MG; IVACAFTOR, TEZACAFTOR 75MG, 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ivacaftor" as an intervention, any sponsor and status, largest first.

All 136 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infective pulmonary exacerbation of cystic fibrosis1,183
  • hospitalisation459
  • infection352
  • cystic fibrosis288
  • pneumonia286
  • headache214
  • cough183
  • cystic fibrosis respiratory infection suppression168
  • pulmonary function test decreased144
  • nausea140
  • dyspnoea135
  • haemoptysis132

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181,201
20193,045
2020801
202188
202238
202339
202439
202529
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 146 on PubMed

Sponsor: Vertex Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.